Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma

Ingo K. Mellinghoff, Benjamin M. Ellingson, Mehdi Touat, Elizabeth Maher, Macarena I. De La Fuente, Matthias Holdhoff, Gregory M. Cote, Howard Burris, Filip Janku, Robert J. Young, Raymond Huang, Liewen Jiang, Sung Choe, Bin Fan, Katharine Yen, Min Lu, Chris Bowden, Lori Steelman, Shuchi S. Pandya, Timothy F. CloughesyPatrick Y. Wen

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

PURPOSE Diffuse gliomas are malignant brain tumors that include lower-grade gliomas (LGGs) and glioblastomas. Transformation of low-grade glioma into a higher tumor grade is typically associated with contrast enhancement on magnetic resonance imaging.Mutations in the isocitrate dehydrogenase 1 (IDH1) gene occur in most LGGs (. 70%). Ivosidenib is an inhibitor of mutant IDH1 (mIDH1) under evaluation in patients with solid tumors. METHODS We conducted a multicenter, open-label, phase I, dose escalation and expansion study of ivosidenib in patients with mIDH1 solid tumors. Ivosidenib was administered orally daily in 28-day cycles. RESULTS In 66 patients with advanced gliomas, ivosidenib was well tolerated, with no dose-limiting toxicities reported. The maximum tolerated dose was not reached; 500 mg once per day was selected for the expansion cohort. The grade≥3 adverse event rate was 19.7%; 3% (n52) were considered treatment related. In patients with nonenhancing glioma (n =35), the objective response rate was 2.9%, with 1 partial response. Thirty of 35 patients (85.7%) with nonenhancing glioma achieved stable disease compared with 14 of 31 (45.2%) with enhancing glioma. Median progression-free survival was 13.6 months (95% CI, 9.2 to 33.2 months) and 1.4 months (95% CI, 1.0 to 1.9 months) for the nonenhancing and enhancing glioma cohorts, respectively. In an exploratory analysis, ivosidenib reduced the volume and growth rates of nonenhancing tumors. CONCLUSION In patients with mIDH1 advanced glioma, ivosidenib 500 mg once per day was associated with a favorable safety profile, prolonged disease control, and reduced growth of nonenhancing tumors.

Original languageEnglish (US)
Pages (from-to)3398-3406
Number of pages9
JournalJournal of Clinical Oncology
Volume38
Issue number29
DOIs
StatePublished - Oct 10 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Ivosidenib in isocitrate dehydrogenase 1-mutated advanced glioma'. Together they form a unique fingerprint.

Cite this